Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMAL H ASSAAD

Allopathic & Osteopathic Physicians Pediatrics Pediatric Allergy/Immunology

NPI
1366491821
CMS profile
658528
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$452.92

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $452.92 4

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Grifols USA, LLC $139.11 1
Regeneron Healthcare Solutions, Inc. $124.99 1
AstraZeneca Pharmaceuticals LP $124.29 1
PFIZER INC. $64.53 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMAL H ASSAAD

NPI 1366491821 · CMS profile ID 658528

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Allergy/Immunology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366491821?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMAL H ASSAAD, NPI 1366491821, CMS profile ID 658528. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366491821?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AMAL H ASSAAD, NPI 1366491821, CMS profile ID 658528. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366491821?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AMAL H ASSAAD, NPI 1366491821, CMS profile ID 658528, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1366491821?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $452.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $124.2909/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685144309 CMS
PFIZER INC. $64.5306/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672504283 CMS
Grifols USA, LLC $139.1105/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692591257 CMS
Regeneron Healthcare Solutions, Inc. $124.9903/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673332411 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $452.92 4
PY2020 $2,483.64 2
PY2021 $75.00 1
PY2022 $264.06 3
PY2023 $3,484.00 4
PY2024 $196.30 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $6,897.44 7
PY2024 Principal investigator $78,048.64 12
PY2023 Principal investigator $280,911.95 38
PY2022 Principal investigator $212,002.48 63
PY2021 Principal investigator $322,169.77 114
PY2020 Principal investigator $211,889.44 47
PY2019 Principal investigator $91,119.00 32

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

114 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $21.42 12/31/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615011
Principal investigator 1 AstraZeneca UK Limited $9,471.96 12/31/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria No dispute reported 06/30/2026 826479639
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $39,257.86 12/28/2021 Non-covered Recipient Entity
CHILDREN'S HOSPITAL MEDICAL CENTER DBA CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614041
Principal investigator 1 ABBVIE INC. $1,204.22 12/21/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386639
Principal investigator 1 ABBVIE INC. $10,302.82 12/02/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386627
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $843.75 12/01/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849612945
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $944.04 12/01/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849612951
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,296.00 12/01/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613057
Principal investigator 1 ABBVIE INC. $1,159.92 11/23/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386621
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $2,000.00 11/15/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613063
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $10,100.00 11/15/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613557
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $18,027.63 11/10/2021 Non-covered Recipient Entity
CHILDREN'S HOSPITAL MEDICAL CENTER DBA CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614035
Principal investigator 1 ABBVIE INC. $1,440.12 11/04/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386609
Principal investigator 1 ABBVIE INC. $54.99 10/19/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386603
Principal investigator 1 ABBVIE INC. $2,943.52 10/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386591
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $378.00 10/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614973
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $189.00 10/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614975
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 10/12/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614965
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 10/12/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614967
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 10/12/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614969
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 10/12/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614971
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 10/12/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615849
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 10/12/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615851
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 10/12/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615853
Principal investigator 1 ABBVIE INC. $100.00 10/08/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386585
Principal investigator 1 GENZYME CORPORATION $364.00 10/05/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 838653425
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $24,609.83 09/21/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615793
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $20,068.00 09/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY No dispute reported 06/30/2026 849615795
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $657.00 09/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615797
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 09/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615799
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 09/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615801
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 09/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615803
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 09/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615805
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $657.00 09/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615807
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 09/14/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615847
Principal investigator 1 ABBVIE INC. $54.99 08/18/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386573
Principal investigator 1 ABBVIE INC. $1,918.02 07/29/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386561
Principal investigator 1 Astellas Pharma Global Development $4,417.00 07/29/2021 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 801079303
Principal investigator 1 SANOFI US SERVICES INC. $311.00 07/20/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable No dispute reported 06/30/2026 838654853
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 07/13/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613331
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 07/13/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613339
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 07/13/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613345
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 07/13/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613351
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 07/13/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613357
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 07/13/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615067
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 07/13/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615069
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $944.04 07/06/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615065
Principal investigator 1 AstraZeneca UK Limited $23,900.00 07/01/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria No dispute reported 06/30/2026 826487451
Principal investigator 1 SANOFI US SERVICES INC. $364.00 07/01/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 838654841
Principal investigator 1 SANOFI US SERVICES INC. $364.00 07/01/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 838654843
Principal investigator 1 SANOFI US SERVICES INC. $364.00 07/01/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 838654845
Principal investigator 1 SANOFI US SERVICES INC. $364.00 07/01/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 838654847
Principal investigator 1 SANOFI US SERVICES INC. $364.00 07/01/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 838654849
Principal investigator 1 SANOFI US SERVICES INC. $364.00 07/01/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 838654851
Principal investigator 1 ABBVIE INC. $3,914.18 06/30/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386549
Principal investigator 1 ABBVIE INC. $100.00 06/23/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386543
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 06/22/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614927
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 06/22/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614929
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $500.00 06/22/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849615063
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $26,282.88 06/08/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614629
Principal investigator 1 ABBVIE INC. $1,440.12 05/27/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386525
Principal investigator 1 ABBVIE INC. $70.18 05/19/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386519
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $708.43 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613187
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $500.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613193
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,906.38 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613199
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,752.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613217
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613223
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $6,789.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613229
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $2,847.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613235
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,971.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613239
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613245
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $2,628.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613251
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $696.60 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613257
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,652.40 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613263
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,134.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613269
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $826.20 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613275
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $567.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613279
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $891.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613285
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $761.40 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613291
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $891.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613299
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613307
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613313
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613319
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613325
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $2,847.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614647
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $4,380.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614649
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $219.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614651
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614671
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $657.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614673
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,095.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614675
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,533.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614719
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,095.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614721
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $3,418.20 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614723
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $2,025.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614725
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $656.10 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614727
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,134.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614759
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,150.20 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614785
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,717.20 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614787
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $761.40 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614789
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $648.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614791
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,458.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614793
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,134.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614795
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $438.00 05/11/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614925
Principal investigator 1 ABBVIE INC. $1,361.44 04/29/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386503
Principal investigator 1 ABBVIE INC. $100.00 04/29/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386509
Principal investigator 1 ABBVIE INC. $350.00 04/13/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386485
Principal investigator 1 ABBVIE INC. $3,500.00 04/13/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386491
Principal investigator 1 SANOFI US SERVICES INC. $364.00 04/08/2021 Non-covered Recipient Entity
Childrens Hospital Medical Center Phoakron
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 838657301
Principal investigator 1 ABBVIE INC. $2,943.52 03/30/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386473
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $1,000.00 03/23/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613211
Principal investigator 1 SANOFI US SERVICES INC. $9,170.00 03/22/2021 Covered Recipient Teaching Hospital
Childrens Hospital Medical Center
A Randomized, Multicenter, 3-arm, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of SAR439794 in Peanut Allergic Adult Patients No dispute reported 06/30/2026 838660923
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $600.00 03/09/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849613205
Principal investigator 1 AIMMUNE THERAPEUTICS, INC. $24,275.70 03/09/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY No dispute reported 06/30/2026 849614627
Principal investigator 1 ABBVIE INC. $3,416.11 01/28/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis No dispute reported 06/30/2026 792386439